TNFRSF9 and kidney cancer: Previously we found that orthotopic Renca tumor was minimally responsive to treatment with a combination of three antibodies (anti-DR5, anti-CD40 and anti-CD137) [11] injected intraperitoneally, and therefore we wished to determine if a different immunotherapy (combining CpG and anti-CD137) could have a better impact on metastatic orthotopic kidney cancer.